Summary
A leading hypothesis of the pathogenesis of neuronal degeneration of the substantia nigra dopamine-containing cells in Parkinson’s disease (PD) is excessive oxidative stress. In part, this oxidative stress is the result of the oxidation of dopamine by the action of monoamine oxidases (MAO) A and B to generate hydrogen peroxide and subsequent oxygen free radicals. Because of this hypothesis we have treated patients with early PD, not yet requiring any symptomatic treatment, with tranylcypromine, a drug that inhibits both MAO’s. These patients were required to observe a tyraminerestricted diet. Thirty-seven patients on tranylcypromine have been followed by us for up to 33 months. Four patients discontinued the drug because of pending surgery. Of the remaining 33, six had adverse effects that lead to discontinuation of the drug, mainly impotency in men. Another common adverse effect encountered was insomnia, but this problem was not a cause of stopping the drug. Depression lifted in all five patients who had this problem at the time tranylcypromine was initiated. Only two patients have so far required treatment with levodopa or a dopamine agonist, and this need occurred within the first 6 months of treatment. The evaluation of all 37 patients revealed that parkinsonian symptoms improved slightly on introduction of tranylcypromine as measured by the Unified Parkinson’s Disease Rating Scale, the Hoehn & Yahr Staging Scale, and the Schwab & England Activities of Daily Living Scale. Follow-up evaluations for a minimum of 6 months between the first post-tranylcypromine visit and the most recent visit revealed only slight worsening of parkinsonian signs and symptoms, with a mean interval of almost 1.5 years. A longer period of follow-up is needed to determine how long the severity of PD will remain mild in this group of patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 20:415–455
Birkmayer W, Knoll J, Riederer P, Youdim MBH (1983) (—)-deprenyl leads to prolongation of L-dopa efficacy in Parkinson’s disease. Mod Probl Pharmacopsychiatry 19: 170–176
Cohen G (1983) The pathobiology of Parkinson’s disease: biochemical aspects of dopamine neuron senescence. J Neural Transm [Suppl 19]: 89–103
Cohen G (1986) Monoamine oxidase, hydrogen peroxide, and Parkinson’s disease. Adv Neurol 45: 119–125
Fahn S (1989) The endogenous toxin hypothesis of the etiology of Parkinson’s disease and a pilot trial of high dosage antioxidants in an attempt to slow the progression of the illness. Ann NY Acad Sci 570: 186–196
Fahn S (1992) A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson’s disease. Ann Neurol 32: S128–S132
Fahn S, Cohen G (1992) The oxidant stress hypothesis in Parkinson’s disease: evidence supporting it. Ann Neurol 32: 804–812
Fahn S, Duffy P (1977) Parkinson’s disease. In: Goldensohn ES, Appel SH (eds) Scientific approaches to clinical neurology. Lea & Febiger, Philadelphia, pp 1119–1158
Fahn S, Elton RL, Members of the UPDRS Development Committee (1987) The Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson’s disease, vol 2. Macmillan Healthcare Information, Florham Park NJ, pp 153–163, 293–304
Fornstedt B, Pileblad E, Carlsson A (1990) In vivo autoxidation of dopamine in guinea pig striatum increases with age. J Neurochem 55: 655–659
Graham DG, Tiffamy SM, Bell WR, Gutknecht WF (1978) Autooxidation versus covalent binding of quinone as the mechanism of toxicity of dopamine, 6-hydro-xydopamine and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 14: 644–653
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442
Hornykiewicz O (1966) Metabolism of brain dopamine in human parkinsonism: neurochemical and clinical aspects. In: Costa E, Côté LJ, Yahr MD (eds) Biochemistry and pharmacology of the basal ganglia. Raven Press, Hewlett NY, pp 171–185
Hornykiewicz O (1982) Brain neurotransmitter changes in Parkinson’s disease. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth Scientific, London, pp 41–58
Jenner P (1991) Oxidative stress as a cause of Parkinson’s disease. Acta Neurol Scand 84: 6–15
Jenner P, Dexter DT, Sian J, Schapira AHV, Marsden CD (1992a) Oxidative stress as a cause of nigral cell death in Parkinson’s disease and incidental Lewy body disease. Ann Neurol 32: S82–S87
Jenner P, Schapira AHV, Marsden CD (1992b) New insights into the cause of Parkinson’s disease. Neurology 42: 2241–2250
Myllyla VV, Sotaniemi KA, Tuominen J, Heinonen EH (1989) Selegiline as primary treatment in early phase Parkinson’s disease — an interim report. Acta Neurol Scand 126: 177–182
Olanow CW (1990) Oxidation reactions in Parkinson’s disease. Neurology 40[Suppl 3]: 32–37
Olanow CW (1992) An introduction to the free radical hypothesis in Parkinson’s disease. Ann Neurol 32: S2–S9
Parkinson Study Group (1989a) Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 321: 1364–1371
Parkinson Study Group (1989b) DATATOP: a multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol 46: 1052–1060
Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early parkinson’s disease. N Engl J Med 328: 176–183
Parkinson Study Group (1995) Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson’s disease. Arch Neurol 52: 237–245
Parkinson Study Group (1996a) Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Ann Neurol 39: 29–36
Parkinson Study Group (1996b) Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Ann Neurol 39: 37–45
Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson’s disease. J Neural Transm 38: 277–301
Schwab RS, England AC Jr (1969) Projection technique for evaluating surgery in Parkinson’s disease. In: Gillingham FJ, Donaldson MC (eds) Third symposium on Parkinson’s disease. E & S Livingstone, Edinburgh, pp 152–157
Spencer JPE, Jenner P, Halliwell B (1995) Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson’s disease. Neuroreport 6: 1480–1484
Tetrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 245: 519–522
Zigmond MJ, Hastings TG, Abercrombie ED (1992) Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson’s disease. Ann NY Acad Sci 648: 71–86
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Wien
About this paper
Cite this paper
Fahn, S., Chouinard, S. (1998). Experience with tranylcypromine in early Parkinson’s disease. In: Finberg, J.P.M., Youdim, M.B.H., Riederer, P., Tipton, K.F. (eds) MAO — The Mother of all Amine Oxidases. Journal of Neural Transmission. Supplement, vol 52. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6499-0_6
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6499-0_6
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83037-6
Online ISBN: 978-3-7091-6499-0
eBook Packages: Springer Book Archive